Patents Examined by Jegatheesan Seharaseyon
  • Patent number: 10877024
    Abstract: The invention provides novel methods of determining or comparing potency of a test interferon relative to rSIFN-co (an interferon having therapeutic effects on solid tumors); methods of establishing substantial equivalence between a test interferon and rSIFN-co; as well as methods for determining potency of a test interferon, kits for determination of such methods, and an interferon or an interferon substitute having said activities.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: December 29, 2020
    Assignee: SUPERLAB FAR EAST LIMITED
    Inventor: Guangwen Wei
  • Patent number: 10874716
    Abstract: The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: December 29, 2020
    Assignee: SUPERLAB FAR EAST LIMITED
    Inventor: Guangwen Wei
  • Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Patent number: 10859572
    Abstract: The invention provides a method for determining a Systemic Lupus Erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table 1, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table 1 is indicative of a Systemic Lupus. The invention also provides an array and a kit suitable for use in the methods of the invention.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: December 8, 2020
    Assignee: Immunovia AB
    Inventors: Carl Arne Krister Borrebaeck, Lars Bertil Christer Wingren
  • Patent number: 10851177
    Abstract: The present disclosure relates to a method for inhibiting intracellular activated (GTP-bound) RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol, and to the use thereof. The disclosure further relates to a heavy-chain variable region (VH) which induces an intact immunoglobulin-type antibody to penetrate the cytosol and bind to activated RAS in the cytosol, and to an antibody comprising the same. The disclosure correspondingly provides a method for inhibiting the growth of cancer or tumor cells using the antibody, and a method for treating cancer or tumor.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: December 1, 2020
    Assignee: ORUM THERAPEUTICS INC.
    Inventors: Yong-Sung Kim, Dong-Ki Choi, Seung-Min Shin, Sung-Hoon Kim
  • Patent number: 10844103
    Abstract: The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: November 24, 2020
    Assignee: Mylan Pharmaceuticals Inc.
    Inventors: Arndt Dietrich, Bernhard Janowski, Jörg Schäffner, Ulrich Kurt Blaschke
  • Patent number: 10829553
    Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 10, 2020
    Assignees: PFIZER INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
  • Patent number: 10822427
    Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a nutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: November 3, 2020
    Assignee: The Regents of the University of California
    Inventors: Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
  • Patent number: 10822421
    Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: November 3, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Kris Reedquist
  • Patent number: 10806799
    Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 20, 2020
    Assignee: GENOPHARM INC.
    Inventors: Young Kee Shin, Young Deug Kim, Jun Young Choi, Tae Eun Kim, Young Jin Lee, Ju Ho Lee, Yeong Mun Kim
  • Patent number: 10799448
    Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 13, 2020
    Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO. LTD
    Inventors: Akira Ito, Takeshi Matsumura, Toru Gotanda, Noriko Tabayashi, Noriko Itchoda, Takashi Aoki, Uiko Kagaya
  • Patent number: 10786551
    Abstract: The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: September 29, 2020
    Assignee: Generon (Shanghai) Corporation Ltd.
    Inventors: Yu Liang Huang, Zhi Hua Huang, Qi Sun
  • Patent number: 10787495
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Patent number: 10787508
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 29, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Patent number: 10781252
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 22, 2020
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Patent number: 10774140
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 15, 2020
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Patent number: 10759854
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 1, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Patent number: 10759852
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 1, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Patent number: 10752691
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 25, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Patent number: 10751416
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 25, 2020
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Michel Gilliet, Jeremy Di Domizio, Stephan Meller